What is the import price of a box of Vigabatrin/vigabatrin in 2025?
Vigabatrin/vigabatrin is a commonly used anti-epileptic drug. Its main function is to inhibit γ-aminobutyric acid aminotransferase and enhance the level of inhibitory neurotransmitters in the central nervous system, thereby effectively controlling epileptic seizures. The drug is available in tablet and oral solution forms. The oral solution is especially suitable for children and the elderly because it is easy to swallow and absorb. With the increase in clinical demand, the sales of Vigabatrin in domestic and foreign markets have also attracted increasing attention.

According to the latest market information,The import price of Vigabatrin will remain within a relatively stable range in 2025. Taking the domestic market as an example, the original version of Vigabatrin oral solution is priced at more than 1,000 yuan per box of 500mg*30 bags. This price has been included in medical insurance, allowing eligible patients to enjoy partial reimbursement policies and reduce their financial burden. In addition, the price of the Turkish version and oral solution dispersible tablets of other countries with the same specifications remains in a similar range, but the specific amount may change due to exchange rate fluctuations. These factors all affect the final cost of drug purchase for patients.
It is worth noting that with the gradual opening of the international market, many patients have begun to choose to purchase overseas generic drugs. For example, the ingredients of generic vigabatrin drugs produced in some countries are basically the same as the original drugs. The average price per box of 500mg*100 bags is about RMB 900. The drug has become the first choice for many patients, especially those facing high medical costs. Compared with original drugs, generic drugs do not have much difference in ingredients. However, due to their lower production costs and more affordable pricing, they can effectively meet the needs of a large number of patients.
Reference materials:https://www.sabril.net/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)